Posts

Venture Capital Pitch Formula

Venture Capital Pitch Formula: https://growthink.infusionsoft.com/go/vcpitch/gt3602/ venture capital, raise venture capital, business financing, business fun…

Shannon Pearson of Venture Capital Radio interviews John McNicol, EnWave Corporation’s President & Co-CEO to learn more about the company and its revolutiona…
Video Rating: 0 / 5

How the venture capital community contributes to Providing Financial Assistance

Most businesses cannot function by themselves. Although they do book profits and look like very healthy enterprises, most of them look for funding from an external source. The need for financial assistance can vary from project to project, and also for different ends to be met. The venture capital community looks to provide funding to the right companies and for the right causes.

There are several reasons for which companies look outside for assistance. There could be the intention to start off with new product categories, or even to enter into new segments. For this, a lot of money is not only required to startup the venture, but also to put processes in place. This is one of the major areas for funding. Additionally, there could be products which look to enter new markets, and this could require a great deal of money, which the venture capital community could readily hand out.

Every project, no matter how new or old, requires periodic research. This is especially true for the pharmaceutical industry, which is one of the major users of venture capital assistance. Venture capitals heavily invest money into most research oriented projects as this is the area where potential exists.

The venture capital community tries to ensure that all the money invested in for the right reasons. Although investing money into a business proposition always comes with some risk, there is plenty of research and study which is involved to pre-empt the possibility of having to lose money in the bargain. Venture capitalists look to improve their reputation and put their money in the right places. It is not very easy to do this, and both the venture capital firm and the company looking for funds have plenty to do before the deal is finally struck.

However, when you have finally signed on the dotted line, there is only plenty to be gained on both sides.

For more information about this article please visit: Venture Capital Community

Focused Capital II Corp. Announces Suspension of Trading

Focused Capital II Corp. Announces Suspension of Trading
About Focused Capital II Corp. Focused Capital II, a capital pool company within the meaning of the policies of the Exchange, was listed on the Exchange on December 28, 2011. Focused Capital II does not have any operations and has no assets other than …
Read more on SYS-CON Media (press release)

Capital Insurance Group Recognizes Gerald R. Becker Insurance Agency with
19, 2014 /PRNewswire/ — Capital Insurance Group® (CIG), has named Gerald R. Becker Insurance Agency as the "2013 North Coast Agency of the Year", an annual award given in recognition of exemplary business performance and customer service. The agency …
Read more on SYS-CON Media (press release)

TIGA Warns UK Games Businesses About Patent Troll Menace
More than 14,000 patent applications were made using the international Patent Co-operation Treaty (PCT) in 2012 – an increase of almost 20 per cent on 2011. … Syndicated stories and blog feeds, all rights reserved by the author. … 2014 – is to …
Read more on SYS-CON Media (press release)

South Africa's venture capital industry with Stephan Lamprecht

(www.abndigital.com) South Africa’s venture capital industry is surprisingly strong for a developing country. That’s one of the findings of a survey conducte…

Venture Capital UK to EU Reform or Were Out! E24

Video Rating: 0 / 5

Video Rating: 0 / 5

Venture Capital: UK to EU – Reform or Were Out (E24)

This week the British Chancellor George Osborne warns the EU that the UK may leave the Union if crucial reforms do not take place. Katie Pilbeam gets very di…
Video Rating: 0 / 5

According to a new PwC US report, “Dollar drought,” that includes data from the PricewaterhouseCoopers LLP/National Venture Capital Association MoneyTree™ Re…

Bstone-Inc.com Promo PRIVATE EQUITY & VENTURE CAPITAL ALLIANCE

Bstone-Inc.com Promo PRIVATE EQUITY & VENTURE CAPITAL ALLIANCE

WELCOME PRIVATE EQUITY & VENTURE CAPITAL ALLIANCE We actualize the growth potential of New Zealand, Asian, East & South African entrepreneurs to build world …
Video Rating: 5 / 5

Panel discussion centered on private equity and venture capital in Latin America. The panel is moderated by Juan Pablo Capello of Greenberg Traurig and featu…
Video Rating: 0 / 5

We are a top-quartile VC investor in India: Sudheer Kuppam, MD, Intel Capital

Intel Capital, the venture capital arm of Intel, the world’s largest semi conductor chip maker, is trying to establish a position sandwiched between extremes…
Video Rating: 5 / 5

Foreign Venture Capital Bullish On China's Pharmaceutical Industry – Wind Investment,

Industry expressed strong interest, investment institutions frequently Pharmaceutical Industry Extending an olive branch. In the recently held Shanghai Shanghai International Symposium on biotechnology and medicine, it was noted that many focus on the pharmaceutical industry, venture capital business owners optimistic about China’s development prospects, investment in China means the wind will be more Chinese characteristics. In Shenzhen, many pharmaceutical companies sought after by venture organization, is now settled that SAIF Asia Investment Fund and Shenzhen Capital Group Ltd, the two sides in the first phase of the Shenzhen Han Yu medicine to 15 million U.S. dollars investment .

Increase the amount of foreign investment

It is understood that the pharmaceutical industry was the first to introduce one of the areas of foreign investment, has about 4000 items total contract amount of more than 15 billion U.S. dollars. However, existing practical realization of investment projects in 1000-2000 amounted to 6 billion U.S. dollars.

Which foreign investment projects in China’s largest pharmaceutical settled down in Shenzhen. 2007, Sanofi? Aventis and the Shenzhen Municipal Government signed the establishment of influenza in Shenzhen Vaccine Production facility agreement, which is by far the largest foreign investment in bio-pharmaceutical projects, an investment of 700 million yuan. Sanofi Pasteur plans to start building the factory, goal for the Chinese market by 2012 production of seasonal influenza vaccine. Sanofi Pasteur to establish this new facility, the purpose is to prepare the event of a human influenza pandemic, or the World Health Organization (WHO) found that a new influenza pandemic strain of influenza during a pandemic vaccine can be produced. Plant design for the Chinese vaccine market is expected to grow leaves room for future expansion.

Experts say the trend of multinational investment in China to set up factories for the early show, from pharmaceutical production to development, distribution, from pharmaceuticals to medical services. According to the Shenzhen Development and Reform Bureau of the person in charge of the construction of Sanofi Pasteur vaccine facility in Shenzhen, is entirely different from the previous repackaging plant, which will bring all the vaccine production process are placed in Shenzhen, including raw materials procurement, production and manufacturing, production of vaccine are mainly exported to Asia, excluding Japan, is expected to reach 1 billion yuan annual output value. Sanofi Pasteur in history, this is the first in France and in vaccine production outside North America Industrial Investment, the company has become the localization of production in China’s first multinational vaccine producers. Can be said that the investment is from multinational companies to meet market demand in China and further extended to build a global production base. “

Actively involved in venture capital Although the return on investment the pharmaceutical industry

long period, high risk, but many focus on the pharmaceutical industry risk fund holders enthusiasm is unabated. Since last year, a number of pharmaceutical companies in South China investment body the wind phase, the Goldman Sachs investment Nepstar, Mindray WIIG investment, investment in the Guangzhou International Data Group, Sandia Hornsey pharmaceutical and medicine, the most recent is John SAIF Investment Yu.

Wind investment agency said, the investment return on the Chinese market than the U.S. market, in the amount of U.S. investment is often the single input high, efficiency is low, the Chinese pharmaceutical industry investment and the return of the wind pretty good. In the direction of investment, the venture investment for the company is more concerned about early. But investors pointed out that the medical information industry, investment, medical services for children and the elderly return faster, similar to the beauty of life can improve the quality of medical research and services are also popular.

In practice, venture funds in China to operate on specific projects and overseas are very different. A venture company partner, venture capital and business objectives will not change, but a number of small and medium enterprises in China for the way quicker ways to achieve goals is not clear, this is a bit worrying. The responsible person said: “We believe that existing technologies in the enterprise itself, a huge market where the key is suitable for transparent financial and human resources.”

Continuous influx of foreign capital in China at the time of the pharmaceutical industry, the capital has also been observed out how best to achieve and how to take a more diversified investment mergers and acquisitions, domestic laws and regulations and property rights trading market should be improved .

SAIF Asia Investment Fund chief Andrew Yan said in an interview, the positive role of foreign investment mainly reflected the improvement in the technical level, management improvement, product introduction, changes in corporate ownership structure and industrial structure change. He said: “We have more in business development and product development in the early stage investment, so no hurry to quit. If the exit, as A-share market re-financing capacity is rather poor, I think a more feasible approach is to bring to the overseas listed companies . ”

I am an expert from China Manufacturers, usually analyzes all kind of industries situation, such as drinking aloe vera juice , lemon juice concentrate.

This week we have Michael Brill, Founder of Crushpad and Stephen Bolger, CEO of Crushpad Bordeaux. For more information, show notes, and an upcoming schedule…

January 2012 monthly – Venture Capital Spurs Start-Ups in Israel

January 2012 monthly - Venture Capital Spurs Start-Ups in Israel

Jan. 24 (Bloomberg) — Bloomberg Television’s Elliott Gotkine reports on business innovation in Israel and access to venture capital by start-ups. (Source: B…